Literature DB >> 23401592

Proteolysis of complement factors iC3b and C5 by the serine protease prostate-specific antigen in prostatic fluid and seminal plasma.

Michael L Manning1, Simon A Williams, Christine A Jelinek, Maya B Kostova, Samuel R Denmeade.   

Abstract

Prostate-specific Ag (PSA) is a serine protease that is expressed exclusively by normal and malignant prostate epithelial cells. The continued high-level expression of PSA by the majority of men with both high- and low-grade prostate cancer throughout the course of disease progression, even in the androgen-ablated state, suggests that PSA has a role in the pathogenesis of disease. Current experimental and clinical evidence suggests that chronic inflammation, regardless of the cause, may predispose men to prostate cancer. The responsibility of the immune system in immune surveillance and eventually tumor progression is well appreciated but not completely understood. In this study, we used a mass spectrometry-based evaluation of prostatic fluid obtained from diseased prostates after removal by radical prostatectomy to identify potential immunoregulatory proteins. This analysis revealed the presence of Igs and the complement system proteins C3, factor B, and clusterin. Verification of these findings by Western blot confirmed the high-level expression of C3 in the prostatic fluid and the presence of a previously uncharacterized C-terminal C3 cleavage product. Biochemical analysis of this C3 cleavage fragment revealed a putative PSA cleavage site after tyrosine-1348. Purified PSA was able to cleave iC3b and the related complement protein C5. These results suggest a previously uncharacterized function of PSA as an immunoregulatory protease that could help to create an environment hospitable to malignancy through proteolysis of the complement system.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23401592      PMCID: PMC4038161          DOI: 10.4049/jimmunol.1200856

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  30 in total

1.  A colorimetric-enzymatic microassay for the quantitation of antibody-dependent complement activation.

Authors:  R F Montaño; S L Morrison
Journal:  J Immunol Methods       Date:  1999-01-01       Impact factor: 2.303

2.  Semenogelin, the predominant protein in human semen. Primary structure and identification of closely related proteins in the male accessory sex glands and on the spermatozoa.

Authors:  H Lilja; P A Abrahamsson; A Lundwall
Journal:  J Biol Chem       Date:  1989-01-25       Impact factor: 5.157

3.  Human prostate-specific antigen: structural and functional similarity with serine proteases.

Authors:  K W Watt; P J Lee; T M'Timkulu; W P Chan; R Loor
Journal:  Proc Natl Acad Sci U S A       Date:  1986-05       Impact factor: 11.205

4.  A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein.

Authors:  H Lilja
Journal:  J Clin Invest       Date:  1985-11       Impact factor: 14.808

5.  Phylogeny of the C3/C4/C5 complement-component gene family indicates that C5 diverged first.

Authors:  A L Hughes
Journal:  Mol Biol Evol       Date:  1994-05       Impact factor: 16.240

6.  Prostate-specific antigen (PSA) is an insulin-like growth factor binding protein-3 protease found in seminal plasma.

Authors:  P Cohen; H C Graves; D M Peehl; M Kamarei; L C Giudice; R G Rosenfeld
Journal:  J Clin Endocrinol Metab       Date:  1992-10       Impact factor: 5.958

7.  Prostate specific antigen cleaves parathyroid hormone-related protein in the PTH-like domain: inactivation of PTHrP-stimulated cAMP accumulation in mouse osteoblasts.

Authors:  S D Cramer; Z Chen; D M Peehl
Journal:  J Urol       Date:  1996-08       Impact factor: 7.450

8.  Functional analysis and quantification of the complement C3 derived anaphylatoxin C3a with a monoclonal antibody.

Authors:  R Burger; A Bader; M Kirschfink; U Rother; L Schrod; I Wörner; G Zilow
Journal:  Clin Exp Immunol       Date:  1987-06       Impact factor: 4.330

9.  Human seminal plasma inhibition of antibody complement-mediated killing and opsonization of Neisseria gonorrhoeae and other gram-negative organisms.

Authors:  G F Brooks; C J Lammel; B H Petersen; D P Stites
Journal:  J Clin Invest       Date:  1981-05       Impact factor: 14.808

10.  Human seminal plasma inhibition of complement.

Authors:  B H Petersen; C J Lammel; D P Stites; G F Brooks
Journal:  J Lab Clin Med       Date:  1980-10
View more
  13 in total

Review 1.  The inflammatory microenvironment and microbiome in prostate cancer development.

Authors:  Karen S Sfanos; Srinivasan Yegnasubramanian; William G Nelson; Angelo M De Marzo
Journal:  Nat Rev Urol       Date:  2017-10-31       Impact factor: 14.432

2.  PSA-alpha-2-macroglobulin complex is enzymatically active in the serum of patients with advanced prostate cancer and can degrade circulating peptide hormones.

Authors:  Maya B Kostova; William Nathaniel Brennen; David Lopez; Lizamma Anthony; Hao Wang; Elizabeth Platz; Samuel R Denmeade
Journal:  Prostate       Date:  2018-04-16       Impact factor: 4.104

3.  The Plethora of Angiotensin-Converting Enzyme-Processed Peptides in Mouse Plasma.

Authors:  Margarita Semis; Gabriel B Gugiu; Ellen A Bernstein; Kenneth E Bernstein; Markus Kalkum
Journal:  Anal Chem       Date:  2019-05-07       Impact factor: 6.986

Review 4.  Complement in cancer: untangling an intricate relationship.

Authors:  Edimara S Reis; Dimitrios C Mastellos; Daniel Ricklin; Alberto Mantovani; John D Lambris
Journal:  Nat Rev Immunol       Date:  2017-09-18       Impact factor: 53.106

5.  Complement opsonization of nanoparticles: Differences between humans and preclinical species.

Authors:  Yue Li; Guankui Wang; Lynn Griffin; Nirmal K Banda; Laura M Saba; Ernest V Groman; Robert Scheinman; S Moein Moghimi; Dmitri Simberg
Journal:  J Control Release       Date:  2021-09-02       Impact factor: 11.467

6.  Lactoferrin CpG Island Hypermethylation and Decoupling of mRNA and Protein Expression in the Early Stages of Prostate Carcinogenesis.

Authors:  Corey M Porter; Michael C Haffner; Ibrahim Kulac; Janielle P Maynard; Javier A Baena-Del Valle; William B Isaacs; Srinivasan Yegnasubramanian; Angelo M De Marzo; Karen S Sfanos
Journal:  Am J Pathol       Date:  2019-09-06       Impact factor: 4.307

Review 7.  Remodelling of the tumour microenvironment by the kallikrein-related peptidases.

Authors:  Srilakshmi Srinivasan; Thomas Kryza; Jyotsna Batra; Judith Clements
Journal:  Nat Rev Cancer       Date:  2022-01-31       Impact factor: 69.800

Review 8.  Auxiliary activation of the complement system and its importance for the pathophysiology of clinical conditions.

Authors:  Markus Huber-Lang; Kristina N Ekdahl; Rebecca Wiegner; Karin Fromell; Bo Nilsson
Journal:  Semin Immunopathol       Date:  2017-09-12       Impact factor: 9.623

Review 9.  Context-dependent roles of complement in cancer.

Authors:  Lubka T Roumenina; Marie V Daugan; Florent Petitprez; Catherine Sautès-Fridman; Wolf Herman Fridman
Journal:  Nat Rev Cancer       Date:  2019-10-30       Impact factor: 60.716

10.  Complement Opsonization Promotes Herpes Simplex Virus 2 Infection of Human Dendritic Cells.

Authors:  Elisa Crisci; Rada Ellegård; Sofia Nyström; Elin Rondahl; Lena Serrander; Tomas Bergström; Christopher Sjöwall; Kristina Eriksson; Marie Larsson
Journal:  J Virol       Date:  2016-04-29       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.